Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02941042 · ClinicalTrials.gov registry record · Phase 1
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT02941042 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 49 participants.
The verdict
NCT02941042, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects being Overweight or with Obesity
Interventions
- DRUG Placebo
- DRUG NNC9204-1177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-10-10 |
| Est. Completion | 2017-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02941042
The ClinicalTrials.gov registry entry for NCT02941042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02941042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02941042 about?
NCT02941042 is a clinical study titled "A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.". Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects being Overweight or with Obesity
What is the current status of trial NCT02941042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2016-10-10. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT02941042?
The interventions under investigation include: Placebo (DRUG), NNC9204-1177 (DRUG).
Who is sponsoring clinical trial NCT02941042?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.